- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Carcinoma of Larynx, Oral Squamous Cell Carcinoma, Salivary Gland Cancer, Adenoid Cystic Carcinoma, Prostate Cancer, Metastatic Castration Resistant Prostate Cancer
- Interventions
- SX-682, DTX
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2037
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Recruitment Status
Recruiting clinical trials
Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
22012
Shown on this page
12
Current sort
Recently updated
Status scope
Recruiting
Additional filters apply within this recruitment status.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 97–108 of 22,012 matching trials with status Recruiting.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- LTI-03, Dry Powder Inhaler, Placebo
- Drug · Device
- Lead sponsor
- Rein Therapeutics
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 16 more
- Conditions
- Glaucoma, Glaucoma, Suspect
- Interventions
- Standard GAT, Fixed force GAT, Upright applanating prototype, Pneumotonometer
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Antenatal Depression
- Interventions
- Sham (placebo) tACS, IAF-tACS, PandA-tACS
- Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Amivantamab, Pembrolizumab, Paclitaxel, Carboplatin
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 15
- States / cities
- La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 12 more
- Conditions
- Solid Tumor
- Interventions
- Non-invasive Comprehensive Genomic Profiling for Cancer Treatment Selection
- Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Crohn Disease
- Interventions
- JNJ-78934804, Guselkumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 29
- States / cities
- Scottsdale, Arizona • Sun City, Arizona • Anaheim, California + 26 more
- Conditions
- Multiple Myeloma
- Interventions
- Ramantamig, Tocilizumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 9
- States / cities
- Goodyear, Arizona • Beverly Hills, California • Irvine, California + 6 more
- Conditions
- Obesity
- Interventions
- Asynchronous Remote Lifestyle Intervention, Synchronous Remote Lifestyle Intervention
- Behavioral
- Lead sponsor
- University of Connecticut
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 378 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Storrs, Connecticut
- Conditions
- Diabetic Retinopathy, Macular Edema
- Interventions
- MK-8748, Aflibercept
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 29
- States / cities
- Gilbert, Arizona • Glendale, California • Sacramento, California + 26 more
- Conditions
- Tics, Functional Tics
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers
- Interventions
- Belzutifan
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Chicago, Illinois • Warrenville, Illinois + 10 more